Tag Archives: SMLP

good buy stocks

What happened

Shares of Bristol-Myers Squibb (NYSE:BMY), a U.S. drug giant that’s primarily focused on oncology, cardiovascular, and immunoscience therapies, catapulted higher by 15% during February, according to data from S&P Global Market Intelligence. The jump in Bristol-Myers’ stock can mostly be attributed to increasing chatter regarding the potential for a buyout.

So what

The real surge in Bristol-Myers’ shares began on Valentine’s Day,when rumors started that Roche, Novartis, and Pfizer were actively exploring the idea of taking over Bristol-Myers, and Gilead Scienceswas tinkering with the idea.

Image source: Getty Images.

Remember, Bristol-Myers Squibb’s stock took a beating after blockbuster cancer immunotherapy drug Opdivo failed to even come close to reaching its primary endpoint in treatment-naive advanced non-small cell lung cancer (NSCLC) patients whose tumors had at least 5% PD-L1 expression (the CheckMate-026 trial). This failure, and the subsequent success of Merck’scompeting cancer immunotherapy Keytruda in a similar indication (greater than 50% PD-L1 expression), shaved billions off Opdivo’s peak sales estimates.

good buy stocks: Oclaro, Inc.(OCLR)

Advisors’ Opinion:

  • [By Evan Niu, CFA]

    Shares of optical component companies have dropped today, includingOclaro (NASDAQ:OCLR), Acacia (NASDAQ:ACIA), Lumentum (NASDAQ:LITE), and Finisar (NASDAQ:FNSR), whose shares were down 11%, 11%, 6%, and 3%, respectively, as of 3:30 p.m. EDT, after the U.S. broadened its investigation regarding compliance with sanctions programs.

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is themostshorted stock on theNASDAQ with short interest of 62.65% according to Highshortnterest.com.

  • [By Arie Goren]

    Advanced Micro Devices, Inc.(NSDQ:AMD)had been by far the best performer in 2016 among all the 413 Russell 3000 tech stocks. Its stock price appreciation of 295.1% in 2016 was significantly higher than the second ranked tech stock NVIDIA Corporation (NVIDIA (NSDQ:NVDA)which gained 223.8% and the third-ranked stock Oclaro Inc. (NSDQ:OCLR)which was up 157.2% in 2016.

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

  • [By Peter Graham]

    Small cap fiber-optic networking product Applied Optoelectronics (NASDAQ: AAOI), a potential peer of EMCORE Corporation (NASDAQ: EMKR), Finisar Corporation (NASDAQ: FNSR) and Oclaro Inc (NASDAQ: OCLR), is thefifth mostshorted stock on theNASDAQ with short interest of 47.69% according to Highshortnterest.com.

good buy stocks: Summit Midstream Partners, LP(SMLP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    More often than not, when a company’s dividend starts approaching 10%, it’susually a sign that the market expects the payout to head lower in the very near future. However, for Summit Midstream Partners (NYSE:SMLP), that doesn’t appear to be the case. That’s because the pipeline and processing company can cover its payout with plenty of room to spare. In fact, it could actually resume distribution growth by year-end. While the company does have a large financial hurdle to overcome in the future, it has plenty of time to find a solution other than cutting the distribution.

good buy stocks: Ingles Markets Incorporated(IMKTA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Not all grocers will suffer from Amazon’s growing reach, but those who sell to high-income customers in the top 25 U.S. markets may see their business erode. Among those names include Costco (COST) , Trader Joe’s and Whole Foods (WFM) , which have the most to lose according to Barclays. On the other hand, Walmart (WMT) , Sam’s Club (owned by Walmart) and Ingle’s Markets (IMKTA)  have the least to lose.

good buy stocks: Rigel Pharmaceuticals Inc.(RIGL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares dropped 22 percent to $2.52 after the company reported results from the second FIT Phase 3 study for fostamatinib. The company disclosed that the study did not meet primary endpoint.

good buy stocks: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By David Zeiler]

    Bill Patalon’s initial stock pick was Galapagos NV (Nasdaq ADR: GLPG), a Belgian biotech company.

    Patalon was attracted to Galapagos’ strategy to target “orphan diseases,” afflictions that strike rarely and so often go ignored by the Big Pharma companies. He also liked that Galapagos had more than 50 drug discovery programs underway, and that it already had licensing agreements with several bigger players in the industry.

  • [By Stephen Mack]

    Galapagos NV (Nasdaq: GLPG) is our big winner so far, gaining 578.8% since Money Morning Executive Editor Bill Patalon shared his recommendation with Money Morning readers in April 2012. The S&P 500 has gained 75.4% in the same time. Bill has renewed his recommendation for the Belgian biotech several times over the years, saying in 2016 that it has “an established history of piling on gains.” With an average gain of 110% a year, it’s hard to argue with that.

Top High Tech Stocks For 2018

Research and development is the lifeblood of biotech companies. The potential for new drugs also serves as a primary factor driving biotech stocks higher and higher. That’s been the case for Celgene (NASDAQ:CELG), Ionis Pharmaceuticals (NASDAQ:IONS), and Ligand Pharmaceuticals (NASDAQ:LGND).

These three biotechs boast some of the most promising pipelines around. Here’s what sets Celgene, Ionis, and Ligand apart from the pack.

Image source: Getty Images.

Celgene: Strong candidates in multiple therapeutic areas

Celgene’s pipeline includes 15 late-stage programs plus two awaiting regulatory approval. Several of those studies are evaluating drugs already on the market in treating additional indications. However, Celgene also claims some new candidates with huge potential.

The big biotech has partnered with Acceleron Pharma on luspatercept. Analysts predict that the drug, which targets blood disorders beta-thalassemia and myelodysplastic syndromes (MDS), could reach peak annual sales of around $2 billion if approved.

Top High Tech Stocks For 2018: Altura Mining Limited (ALTAF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By SEEKINGALPHA.COM]

    The question now is more about speed of EV implementation. On the supply side, it has been great to see LAC, Pilbara Minerals (OTCPK:PILBF) and Altura Mining (OTCPK:ALTAF) get funding, but the continued issues with Albemarle’s (NYSE:ALB) LaNegra II expansion and Orocobre (OTCPK:OROCF) ramping up to Phase 1 capacity of 17,500 tonnes/year of lithium carbonate are further evidence that lithium projects take time and have considerable execution risk.

Top High Tech Stocks For 2018: Summit Midstream Partners, LP(SMLP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    More often than not, when a company’s dividend starts approaching 10%, it’susually a sign that the market expects the payout to head lower in the very near future. However, for Summit Midstream Partners (NYSE:SMLP), that doesn’t appear to be the case. That’s because the pipeline and processing company can cover its payout with plenty of room to spare. In fact, it could actually resume distribution growth by year-end. While the company does have a large financial hurdle to overcome in the future, it has plenty of time to find a solution other than cutting the distribution.

Top High Tech Stocks For 2018: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By Chris Lange]

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Tuesday following its presentation at the JPMorgan Healthcare Conference. The companys Duchenne muscular dystrophy (DMD) drug, Exondys 51, generated better than expected sales clocking in at $5.4 million in the fourth quarter. Previously, this DMD treatment was approved by the FDA just as recently as September 2016.

  • [By Ben Levisohn]

    After surveying 30 neurologists, Baird’s Brian Skorney and Neena Bitritto-Garg contend that the Street might be underestimating sales of Sarepta Therapeutics (SRPT) Exondys 51 treatment for patients with Duchenne muscular dystrophy. They explain why:

  • [By Lisa Levin]

    Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were also up, gaining 16 percent to $47.52 following the announcement of positive results in its study for the treatment of Duchenne Muscular Dystrophy.

  • [By Johanna Bennett]

    Will healthinsurers pay for Sarepta Therapeutics (SRPT) Exondys 51?

    Thats a question that several analysts have weighed on today. It appears that payors are still actively evaluating and reevaluating coverage of the Duchenne muscular dystrophy drug Exondys 51.

    Approved by the FDA in September, the drug has met with widespread pushback from insurers like Anthem (ANTM), Humana (HUM) and UnitedHealth Group (UNH) amid concerns about its efficacy. So while Sareptas share price has more than doubled over the past 12 months, it has made a sharp retreat, falling 50% to just under $32 a share since hitting a record high $63.73 a share in late September.

    But Cowen analyst Ritu Baral says the tide maybe turning, arguing that coverage denials wont be permanent.

    As SRPT management and our Neuromuscular Disease panelist indicated to us at our recent Healthcare Conference, payor discussions are continuing regarding Exondys 51 with manageable, increasingly positive feedback. Of the major plans we have seen coverage policies released for, only Anthem (including Blue Cross Blue Shield) had previously denied coverage of Exondys, though patients could petition for coverage via a standard appeal process (see further below). Based on their February Specialty Pharmacy Medical Management Prior Authorization Drug List, it appears Anthem will add Exondys 51 to its prior auth list as of 5/1. We think this is encouraging and indicative of the evolving payor landscape surrounding Exondys 51 and more broadly, DMD. Anthem’s pick-up, together with those such as United, which started coverage on 2/1, support the idea of accelerating new patient starts, suggested by SRPT last week at our Healthcare Conference.

    …But Coverage Denials Persist (For Now), Especially Among Non-Ambulatory Patients. While we think the overwhelming majority of amenable patients will eventually be covered for Exondys 51, we do note several social media anecdote

top ten stocks today

Verizon Communications Inc. (NYSE: VZ) replaces Exxon Mobil this week as the worst-performing stock on the Dow Jones Industrial Average (DJIA) index, a position it last held in February. The stock has lost 8.84% for the year to date.

The shares dropped by just 9 cents last week (less than 0.2%), but that was enough to drop the stock to the bottom of the Dow 30.

Investors remain concerned about the hit to revenues that may follow the adoption of the company’s unlimited data plan. With all four major U.S. wireless carriers now offering unlimited data plans, has the industry embarked on a race to the bottom?

Analysts at Jefferies warned:

While the industry remains bullish on growth in data usage, and metered plans allow for some continued enthusiasm, the move by every carrier to unlimited plans will cause carriers to hope for less and less data usage. Almost every pricing action over the last couple of years has continued to take the roof down on ARPU growth opportunities as more and more data was offered for the same, or lower price point. Now with the advent of unlimited plans, the upside from additional usage is gone for those choosing aggressively priced unlimited plans.

top ten stocks today: Summit Midstream Partners, LP(SMLP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    More often than not, when a company’s dividend starts approaching 10%, it’susually a sign that the market expects the payout to head lower in the very near future. However, for Summit Midstream Partners (NYSE:SMLP), that doesn’t appear to be the case. That’s because the pipeline and processing company can cover its payout with plenty of room to spare. In fact, it could actually resume distribution growth by year-end. While the company does have a large financial hurdle to overcome in the future, it has plenty of time to find a solution other than cutting the distribution.

top ten stocks today: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Note that hedge fund mogul David Einhorn has been a director ofthe predecessor company since May 2006. Mr. Einhorn co-founded, and has served as the President of, Greenlight Capital, Inc., since January 1996. Funds managed by Greenlight are some ofthe Companys principal stockholders. Since July 2004, Mr. Einhorn has served as Chairman of the Board of Greenlight Capital Re, Ltd (Nasdaq: GLRE).

top ten stocks today: Exa Corporation(EXA)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Monica Gerson]

    Exa Corp (NASDAQ: EXA) is projected to post a quarterly loss at $0.08 per share on revenue of $16.68 million.

    Thermon Group Holdings Inc (NYSE: THR) is estimated to report its quarterly earnings at $0.19 per share on revenue of $65.24 million.

top ten stocks today: KBR, Inc.(KBR)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    KBR (KBR) was upgraded to buy from neutral at Bank of America/Merrill Lynch. $20 price target. The company is leveraged to higher defense spending and is attractively valued, analysts said. 

top ten stocks today: Panasonic Corporation (PCRFY)

Advisors’ Opinion:

  • [By Ben Levisohn]

    During the early stages of a new innovation, interdependent architectures and integrated companies best optimize performance and functionality. This trend has played out in computing and handsets, and we see the same trend playing out in EVs. We find Tesla and BYD1 , by far, the most vertically integrated players in EVs, with huge scale advantages. In addition, LG Chem, Panasonic (PCRFY), Samsung SDI, BYD, and CATL are clear scale leaders in batteries (CATL is not publicly traded. All but Samsung SDI and BYD are not covered by Bernstein.).

  • [By SEEKINGALPHA.COM]

    Clean Technica reported on September 1 that “Sony is entering the EV battery manufacturing industry”. And “considering that electric vehicle batteries are going to be the main supply bottleneck for the upcoming auto market’s embrace of EVs, the entry of Sony into the field is very notable. Most of the other manufacturers (Panasonic (OTCPK:PCRFY), LG Chem (OTC:LGCLF), etc.) already have more or less all of their production capacity locked up for the coming years – meaning there’s not much left for the auto manufacturers that are running behind, thereby limiting potential EV sales for the firms in question. Sony’s (NYSE:SNE) entry into the field should open things up a bit more”. Certainly a good move by Sony and helpful for the EV companies that will find themselves in need of batteries, and limited availability, should EVs reach 10% by 2020.

  • [By SEEKINGALPHA.COM]

    A Unilever vs. Panasonic (OTCPK:PCRFY) showdown seems to be something out of an alternative, weird universe. But that’s exactly what has been happening in the Asia-Pacific region, where Unilever is now a major seller of air and water purification devices. The acquisitions of Qinyuan and Pureit water purifiers, as well as the acquisition of Sweden-based Blueair in 2016, reflects Unilever’s latest growth strategy of reducing exposure to low-growth brands in favor of greater investments in higher-growth products with strong social and environmental credentials.

  • [By SEEKINGALPHA.COM]

    JOLED is a company that was established in 2014 by by Japan Display, Sony (NYSE:SNE) and Panasonic (OTCPK:PCRFY). And they are not the only ones:

    During an OLED display Seminar in Korea, UniJet’s CEO Kim Seok-Soon said that new advances in Ink-Jet printing technologies could enable displays that are over 500 PPI – and so make printing a viable technology to produce small and medium-sized OLED panels.

top ten stocks today: ENI S.p.A.(E)

Advisors’ Opinion:

  • [By Dustin Parrett]

    Big Oil stocks are the seven “oil supermajors” that do everything from oil drilling to refining to retail sales. This is a list of the Big Oil companies:

    Big Oil CompanyShare PriceYTDMarket CapExxon Mobil Corp. (NYSE: XOM)$83.44-7.58%$353.13BChevron Co. (NYSE: CVX)$113.56-3.5%$217.62BConocoPhillips Co. (NYSE: COP)$48.21-3.78%$61.42BRoyal Dutch Shell Plc. (NYSE ADR: RDS.A)$52.35-3.82%$221.08BBP Plc. (NYSE ADR: BP)$34.12-8.71%$112.69BTotal SA (NYSE: TOT)$50.26-1.35%$124.6BEni SpA (NYSE: E)$31.51-2.3%$58.69B

    Despite being huge global oil companies, shares of Big Oil stocks are all in the red this year. Those losses have all happened even as the Dow is smashing record highs and trading up 6.4% year to date.

  • [By Paul Ausick]

    Reuters reported last week that the company is considering selling its 2,500 service stations in Italy for a tidy 500 million (about $538 million). The rumored buyer is private equity giant Apollo Global Management LLC (NYSE: APO), also rumored to be interested in buying 2,600 Italian service stations from a joint venture between Italy’s Eni SpA (NYSE: E) and Total SA (NYSE: TOT).

  • [By Dustin Parrett]

    Specifically, the oil supermajors are ExxonMobil Corp. (NYSE: XOM), BP Plc. (NYSE: BP), Chevron Corp. (NYSE: CVX), Royal Dutch Shell Plc. (NYSE ADR: RDS.A), Conoco Phillips (NYSE: COP), Eni SpA (NYSE ADR: E), and Total SA (NYSE ADR: TOT).